[Webinar] How to better optimize an oncology drug discovery program
Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.Read more
Bengt Erik Haug, Ketil André Camilio, Liv Tone Eliassen, Wenche Stensen, John Sigurd Svendsen, Kristel Berg, Bjarte Mortensen, Guillaume Seri, Jean-Francois Mirjolet, Francis Bichat, and Øystein Rekdal
Oncolytic immunotherapies represent a new promising strategy in the treatment of cancer. In our efforts to develop oncolytic peptides, we identified a series of chemically modified 9-mer cationic peptides that were highly effective against both drug-resistant and drug-sensitive cancer cells and with lower toxicity toward normal cells. Among these peptides, LTX-315 displayed superior anticancer activity and was selected as a lead candidate. This peptide showed relative high plasma protein binding abilities and a human plasma half-life of 160 min, resulting in formation of nontoxic metabolites. In addition, the lead candidate demonstrated relatively low ability to inhibit CYP450 enzymes. Collectively these data indicated that this peptide has potential to be developed as a new anticancer agent for intratumoral administration and is currently being evaluated in a phase I/IIa study.
Ref: J. Med. Chem. 2016, 59, 7, 2918–2927 https://doi.org/10.1021/acs.jmedchem.5b02025